Search

Placental Mesenchymal Stem Cells

The placenta serves many purposes, with one of the many being a bank of mesenchymal stem cells (MSCs). … It can be obtained relatively easily as medical waste from which MSCs can be non-invasively extracted and without the ethical issues that come with embryonic stem cells.

AT-301

AT-301 was under investigation in clinical trial NCT01675284 to evaluate the safety, reactogenicity, and humoral immune responses to an inactivated H5N1 influenza vaccine

Grapiprant

These molecules were derived from acylsulfonamide and are characterized to be a novel series of para-N-acylaminomethylbenzoic acid known to be prostaglandin receptor antagonists. … Grapiprant, also known as AT-001 and CJ-023, is a drug from the piprant class.

Prednisolone phosphate

[A187463] Prednisolone phosphate was granted FDA Approval on 19 December 1973.[L14144] … Prednisolone phosphate is a glucocorticoid similar to [cortisol] used for its anti-inflammatory, immunosuppressive, anti-neoplastic, and vasoconstrictive effects.

Sulfanilamide

Sulfanilamide is a molecule containing the sulfonamide functional group attached to an aniline.

Rocaglamide

[A186760] Rocaglamides are secondary metabolites of the plant genus _Aglaia_, and extracts of the plant have traditionally been used as a form of insect repellant due to its natural insecticidal properties … Rocaglamide, also referred to as rocaglamide-A, is the eponymous member of a class of anti-cancer phytochemicals known as rocaglamides.

Iron protein succinylate

Paramethadione

Paramethadione is an anticonvulsant in the oxazolidinedione class. It is associated with fetal trimethadione syndrome, which is also known as paramethadione syndrome.

Omapatrilat

This drug from BMS was not approved by the FDA due to angioedema safety concerns. … Omapatrilat is an investigational drug that inhibits both neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE).

Aclidinium

Aclidinium is an anticholinergic for the long-term management of chronic obstructive pulmonary disease (COPD). … It has a much higher propensity to bind to muscarinic receptors than nicotinic receptors. FDA approved on July 24, 2012.